(AZTA) Azenta, Inc. Business Model Canvas Research

Azenta, Inc. works with academic and research collaborators to plug its tools into daily scientific workflows in universities and private labs. These partners help drive use of discovery and biospecimen services, while giving Azenta real-world validation in live research settings.

• Supports university and private lab workflows
• Expands discovery and biospecimen use
• Validates products in real research

Azenta uses regional distributors and service partners to widen commercial reach across North America, Europe, Asia Pacific, and China, while keeping local sales, installation, and support close to customers. This matters for a global installed base of 500,000+ sample management assets, where fast regional service can cut downtime and improve adoption.

• Expand local market access
• Deliver on-site installation
• Speed up service response
• Support global customers locally

Azenta, Inc. runs genomic and lab services through GENEWIZ, covering sequencing, gene synthesis, lab processing, and analysis to help research and drug development teams move faster. This shifts Azenta beyond product sales into recurring service execution, a key driver in its life science tools model.

• Sequencing and synthesis
• Lab processing and analysis
• Research and drug development support
• Services beyond product sales

Azenta’s biospecimen acquisition and informatics activity ties sample intake to sample data, so each specimen can be traced through collection, storage, and use. That matters in a market where research teams need clean, audit-ready records; Azenta serves biopharma, academic, and clinical customers with sample logistics and digital chain-of-custody tools.

• Links physical samples to digital records
• Improves traceability and audit readiness
• Supports research workflows end to end

In fiscal 2025, Azenta reported revenue of about $625 million, and this activity helps protect that base by keeping samples usable, searchable, and compliant.

Service labs and informatics platforms anchor Azenta, Inc.'s services business by supporting sequencing, gene synthesis, processing, analysis, and sample management. In fiscal 2025, this model stayed tied to recurring lab demand, while informatics tools connected storage, logistics, and lab workflows into one chain.

• Supports end-to-end lab services
• Links storage, logistics, workflows
• Drives recurring service revenue

These resources are core to delivery speed, sample traceability, and scale.

Azenta, Inc.’s headquarters in Chelmsford, Massachusetts, is the corporate base for management, governance, and coordination across its global life-science platform. It anchors the operating model for a company serving customers in 60+ countries, with the site central to strategy, oversight, and execution.

• Corporate control center
• Supports global governance
• Anchors operating structure

The Chelmsford hub helps align product, service, and capital decisions for Azenta’s FY2025 business, which reported revenue of about $650 million, making the headquarters a key resource for disciplined execution.

Azenta, Inc. speeds research and drug development by linking sequencing, analysis, and sample management in one workflow, so teams can move from sample intake to R&D decisions faster. This makes its sample infrastructure a direct input to downstream drug programs, not just a storage layer.

• Sequencing, analysis, and sample control
• Faster drug development cycles
• Sample data tied to R&D outcomes

Azenta’s end-to-end sample support covers sample banking, cold-chain logistics, lab processing, and biospecimen acquisition, so customers can move from collection to analysis with one partner. This broad sample-centric offer strengthens workflow control and supports recurring service demand across the sample lifecycle.

• One partner from collection to analysis
• Combines storage, logistics, processing
• Builds a sample-centric offering

Azenta, Inc. builds customer ties around project-based scientific work, with sequencing, gene synthesis, and lab services shaped by each study’s scope, timeline, and data needs. That makes the relationship consultative: Azenta helps design and run the workflow, not just sell a standard service.

• Project-specific sequencing and synthesis
• Lab work matched to study needs
• Consultative, high-touch support

Global key-account management fits Azenta, Inc.’s international reach by giving large customers one coordinated team across regions, so multinational buyers get the same pricing, service, and support. This matters for accounts that place repeat orders across labs and sites in North America, Europe, and Asia, where 2025 demand stayed tied to life-science workflow spending.

• One team for multi-region buying
• Supports global pricing and service
• Matches Azenta’s international footprint

Azenta, Inc.’s informatics-enabled service access links sample data, workflows, and support in one digital layer, so customers can manage orders beyond the lab bench. That matters at scale: Azenta serves global life sciences users through connected systems that tie operations to data, speeding coordination and reducing handoffs.

• Digital access supports sample tracking
• Workflows stay visible end to end
• Data and operations stay linked

Azenta uses logistics and distribution networks to move samples, consumables, and instruments to customer sites and labs, with cold-chain handling built for time-sensitive shipments. This matters in life sciences, where sample integrity depends on tight temperature control, from ambient to cryogenic ranges as low as -196°C.

Its network extends Azenta’s reach beyond direct sales, helping serve labs that need fast replenishment and secure delivery. In 2025, this channel still matters most where delays can damage samples, disrupt workflows, and raise cost per shipment.

• Supports sample, consumable, and instrument delivery
• Protects cold-chain and urgent shipments
• Extends access to customer sites and labs

Academic research institutions use Azenta’s sequencing, sample handling, and lab services for long-running studies that need specialized equipment and controlled workflows. This is a recurring scientific base: Azenta reported roughly $650 million in FY2025 revenue, showing steady demand tied to research projects, biobanking, and genomics support.

• Sequencing for discovery work
• Sample handling for scale and traceability
• Lab services for niche workflows
• Repeat use from research programs

Private research institutions run proprietary discovery and development programs, so they need sample-centric workflows that link storage, tracking, automation, and lab services in one chain. Azenta, Inc. fits that use case by combining products with outsourced lab support, which helps teams move faster without building every capability in-house.

• Proprietary discovery needs integrated sample services.
• Equipment plus lab support lowers in-house load.
• Best fit for complex, sample-heavy R&D.

Logistics and cold-chain expenses cover transport, storage, and 2°C–8°C or -80°C handling, which protects sample integrity and on-time delivery for Azenta, Inc.'s global network. Cold-chain logistics is a costly but critical layer in life sciences, where even small temperature excursions can destroy high-value samples and delay service.

• Transport, storage, and temperature control

• Protects sample integrity

• Supports global service delivery

Azenta’s selling, general, and administrative costs fund commercial teams, corporate functions, and global infrastructure, so they are the backbone of a worldwide life-science business. In fiscal 2025, this line item remained a major fixed cost as Azenta served customers across North America, Europe, and Asia, supporting sales, compliance, IT, finance, and regional operations.

• Commercial reach across regions
• Corporate support and compliance
• Global systems for service delivery

These costs matter because Azenta sells complex tools and services that need local coverage, fast support, and centralized controls. That structure helps the Company scale internationally, but it also keeps SG&A under pressure when revenue growth slows.

Azenta, Inc. earns sequencing and gene synthesis revenue from research and drug development workflows, where labs pay for high-value, repeat testing and custom DNA builds. These services sit close to R&D budgets, so they support sticky, higher-margin lab income rather than one-off product sales.

In fiscal 2025, Azenta reported about $650 million in revenue, with lab services tied to genomics and synthesis helping offset softer hardware demand. The revenue mix matters because custom sequence work and gene synthesis usually recur across discovery, validation, and translational studies.

• Linked to R&D and drug discovery
• Supports repeat, higher-value lab income
• FY2025 revenue was about $650 million

Azenta, Inc. earns lab processing, analysis, and biospecimen acquisition fees from sample-centric research programs, turning one sample into multiple paid steps across the lifecycle. In FY2025, this kind of services mix helped lift recurring, higher-margin revenue tied to research demand and biobanking workflows.

• Lab work and analysis drive service fees
• Biospecimen acquisition adds another revenue layer
• Extends monetization across the sample lifecycle